Summary

Eligibility
for people ages 6 months to 36 months (full criteria)
Location
at UCLA
Dates
study started
estimated completion
Principal Investigator
by Peter G Szilagyi, MD, MPH (ucla)
Photo of Peter G Szilagyi
Peter G Szilagyi

Description

Summary

This trial is taking place in Los Angeles, CA among patients from primary care practices within the UCLA Health System. The study design is a parallel 2-arm trial. The parallel arms are 1) a reminder letter for the second dose of influenza vaccine (reminder messages sent via the patient portal) with a direct appointment scheduling link included in the reminder and 2) a reminder letter for the second dose of influenza vaccine, but no direct appointment scheduling link included.

Official Title

Patient Portal Reminder/Recall for Influenza Vaccination in the UCLA Health System- Pediatric Second Dose

Details

This trial is taking place in Los Angeles, CA among patients from primary care practices within the UCLA Health System, using a parallel 2-arm trial. Sub-optimal vaccination rates are a significant problem in the U.S., despite their effectiveness in preventing morbidity and mortality from vaccine-preventable illness. In the U.S., annual epidemics of influenza cause substantial morbidity in the U.S. with up to 40,00-80,000 deaths/year and many hospitalizations, emergency and outpatient visits, and significant costs. Young children-especially those younger than 2- are at high risk of developing serious flu-related complications. Children ages of 6 months to 8 years getting vaccinated for the first time with influenza vaccine should get two doses, and those who have only previously gotten one dose of influenza vaccine, should get a second dose (spaced at least 4 weeks apart). Reminder/recall (R/R) messages, sent by phone, mail or other modality, can improve child vaccination rates. However, the majority of pediatric or adult primary care practices to not conduct R/R. Barriers are lack of finances, personnel, and algorithms to identify eligible patients. A technological breakthrough that might overcome these barriers involves patient portals-- secure, web-based communication systems, embedded within electronic health records (EHRs), for patients and providers to communicate with each other via email and the internet. Portals are increasingly used by healthcare systems. This randomized controlled trial will assess the effectiveness of reminders messages, sent to the proxy of pediatric patients ages 6 months to <36 months of age eligible for a second dose of the influenza vaccine based on data in the EHR. Patients will be randomized into one of two arms to receive 1) a reminder letter for a second dose of influenza vaccine, with a direct appointment scheduling link included in the letter or 2) a reminder letter for a second dose of influenza vaccine, without a direct appointment scheduling link included in the letter.

Keywords

Influenza Respiratory Tract Infections Vaccination Reminder Recall Patient Portal Influenza, Human Vaccines

Eligibility

You can join if…

Open to people ages 6 months to 36 months

  • Patient within the UCLA Health System identified as a primary care patient per an internal algorithm
  • Identified as being overdue for a second dose of influenza vaccine.

You CAN'T join if...

  • Patient within the UCLA Health System not identified as a primary care patient per an internal algorithm
  • Not due for a second dose of influenza vaccine.

Location

  • University of California LA
    Los Angeles California 99095 United States

Lead Scientist at UC Health

  • Peter G Szilagyi, MD, MPH (ucla)
    Dr. Peter Szilagyi is a pediatric health services and clinical researcher with an overall mission to improve access to healthcare, quality of care, and health outcomes for children.

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Los Angeles
ID
NCT04668417
Study Type
Interventional
Last Updated